Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

Sentiment towards telecoms testing firm sours as it warns on 2023
Thursday 26 Jan 2023 Author: Tom Sieber

Spirent (SPT) 226.6p

Loss to date: 17.6%

We flagged the appeal of telecoms testing firm Spirent (SPT) at 275p on 12 January, seeing it as a smart way to play the rollout of 5G mobile network infrastructure. Sadly, a 20 January trading update materially undermined this hypothesis.

WHAT’S HAPPENED SINCE WE SAID TO BUY?

Spirent provides testing, analytics and security services to the telecommunications space and it was a warning of hesitancy on the part of this customer base which really rocked sentiment towards the company and saw the shares drop more than 20% at one point, falling way below our entry point.

The Crawley-based business at least confirmed guidance for 2022 – with profit slightly ahead of the market consensus of $127 million – a 7.2% year-on-year increase. The order book was also up 7% in the year. However, delays are now expected to see a ‘heavier than usual’ second-half weighting for 2023.

Broker Canaccord Genuity painted a bleaker picture noting that the 9% organic growth in the first three quarters of 2022 creates a demanding comparison for the next nine months.

It adds: ‘Our analysis further indicates capex spend by Spirent’s largest customer group, the US service providers (20%-plus of sales), has peaked and will likely decline by a double-digit percentage over the next couple of years. Factoring in likely further operating/capital expenditure budget tightening among Spirent’s other customers, in our view, makes meaningful outperformance of 4% consensus revenue growth expectations less likely this year.’

WHAT SHOULD INVESTORS DO NOW?

If spending by Spirent’s largest customers on 5G has peaked for the time being, then a central part of our reason for recommending the shares has gone. In these circumstances it seems sensible to take our medicine (painful as it is) and walk away with 17.6% loss. Particularly as there appear limited catalysts in the short term which could get the share price moving again.


‹ Previous2023-01-26Next ›